Latest Biotechnology Finance News

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.